# Zackery P Bulman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4979521/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 38 papers | 797 citations | 516710 16 h-index | 552781 26 g-index |
| 39 all docs | 39 docs citations | 39 times ranked | 1046 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2022, 77, 356-363. | 3.0 | 12 |
| 2 | Antibiotic susceptibility patterns of viridans group streptococci isolates in the United States from 2010 to 2020. JAC-Antimicrobial Resistance, 2022, 4, . | 2.1 | 7 |
| 3 | Research priorities towards precision antibiotic therapy to improve patient care. Lancet Microbe, The, 2022, 3, e795-e802. | 7.3 | 17 |
| 4 | Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant Acinetobacter baumannii with Polymyxin-Based Combinations. Antibiotics, 2022, 11, 959. | 3.7 | 5 |
| 5 | Ceftazidime-avibactam based combinations against carbapenemase producing Klebsiella pneumoniae harboring hypervirulence plasmids. Computational and Structural Biotechnology Journal, 2022, 20, 3946-3954. | 4.1 | 1 |
| 6 | Optimizing aminoglycoside selection for KPC-producing Klebsiella pneumoniae with the aminoglycoside-modifying enzyme (AME) gene aac(6â€™)-Ib. Journal of Antimicrobial Chemotherapy, 2021, 76, 671-679. | 3.0 | 9 |
| 7 | Therapeutic Options for Metallo-Î²-Lactamase-Producing Enterobacterales. Infection and Drug Resistance, 2021, Volume 14, 125-142. | 2.7 | 45 |
| 8 | In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae. Frontiers in Microbiology, 2021, 12, 618087. | 3.5 | 4 |
| 9 | Capability ofEnterococcus faecalisto shield Gram-negative pathogens from aminoglycoside exposure. Journal of Antimicrobial Chemotherapy, 2021, 76, 2610-2614. | 3.0 | 3 |
| 10 | Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2021, 65, e0069221. | 3.2 | 9 |
| 11 | Genomic Features Associated with the Degree of Phenotypic Resistance to Carbapenems in Carbapenem-Resistant Klebsiella pneumoniae. MSystems, 2021, 6, e0019421. | 3.8 | 26 |
| 12 | In Vitro Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant Enterococcus faecium and Carbapenem-Resistant Enterobacter cloacae Bacteremia in a Liver Transplant Patient. Open Forum Infectious Diseases, 2020, 7, ofz545. | 0.9 | 5 |
| 13 | Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 21 |
| 14 | Unraveling the Gentamicin Drug Product Complexity Reveals Variation in Microbiological Activities and Nephrotoxicity. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 10 |
| 15 | A coup d'Ã©tat by NDM-producing Klebsiella pneumoniae overthrows the major bacterial population during KPC-directed therapy. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115080. | 1.8 | 3 |
| 16 | Rational Combinations of Polymyxins with Other Antibiotics. Advances in Experimental Medicine and Biology, 2019, 1145, 251-288. | 1.6 | 21 |
| 17 | Inoculum effect of Î²-lactam antibiotics. Journal of Antimicrobial Chemotherapy, 2019, 74, 2825-2843. | 3.0 | 83 |
| 18 | Shifting Gears: The Future of Polymyxin Antibiotics. Antibiotics, 2019, 8, 42. | 3.7 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study. Infectious Diseases, 2019, 51, 287-292. | 2.8 | 9 |
| 20 | Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat. Current Infectious Disease Reports, 2019, 21, 46. | 3.0 | 47 |
| 21 | Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model. International Journal of Antimicrobial Agents, 2018, 52, 114-118. | 2.5 | 5 |
| 22 | Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 13 |
| 23 | High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 60 |
| 24 | A combination of ceftaroline and daptomycin has synergistic and bactericidal activityin vitroagainst daptomycin nonsusceptible methicillin-resistantStaphylococcus aureus(MRSA). Infectious Diseases, 2017, 49, 410-416. | 2.8 | 23 |
| 25 | New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 14 |
| 26 | Pharmacodynamics of colistin and fosfomycin: a â€˜treasure troveâ€™ combination combats KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2017, 72, 1985-1990. | 3.0 | 43 |
| 27 | Pharmacodynamics of dose-escalated â€˜front-loadingâ€™ polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli. Journal of Antimicrobial Chemotherapy, 2017, 72, 2297-2303. | 3.0 | 14 |
| 28 | Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and bla<sub>NDM-5</sub> : Preparation for a Postantibiotic Era. MBio, 2017, 8, . | 4.1 | 50 |
| 29 | In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against Î²-lactamase-producing Escherichia coli in a hollow-fibre infection model. International Journal of Antimicrobial Agents, 2017, 49, 25-30. | 2.5 | 8 |
| 30 | Native valveProteus mirabilisendocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing. BMJ Case Reports, 2016, 2016, bcr2016215956. | 0.5 | 6 |
| 31 | Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2016, 60, 2870-2880. | 3.2 | 18 |
| 32 | Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 1584-1591. | 3.2 | 18 |
| 33 | Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined Î²-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of Î²-Lactamâ€“Î²-Lactamase Inhibitor Combinations. Antimicrobial Agents and Chemotherapy, 2016, 60, 1967-1973. | 3.2 | 11 |
| 34 | Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infectious Diseases and Therapy, 2015, 4, 391-415. | 4.0 | 45 |
| 35 | Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use. Pharmacotherapy, 2015, 35, 34-42. | 2.6 | 52 |
| 36 | Evolution of Staphylococcus aureus under Vancomycin Selective Pressure: the Role of the Small-Colony Variant Phenotype. Antimicrobial Agents and Chemotherapy, 2015, 59, 1347-1351. | 3.2 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Emergence of Polymyxin B Resistance Influences Pathogenicity in Pseudomonas aeruginosa Mutators. Antimicrobial Agents and Chemotherapy, 2015, 59, 4343-4346. | 3.2 | 5 |
| 38 | A novel property of propolis (bee glue): Anti-pathogenic activity by inhibition of N-acyl-homoserine lactone mediated signaling in bacteria. Journal of Ethnopharmacology, 2011, 138, 788-797. | 4.1 | 29 |